产品说明书

Ellagic acid

Print
Chemical Structure| 476-66-4 同义名 : Gallogen;Elagostasine;HSDB 7574;CCRIS 774;Benzoaric acid;Alizarine Yellow;TBBD;Lagistase
CAS号 : 476-66-4
货号 : A106247
分子式 : C14H6O8
纯度 : 98%
分子量 : 302.193
MDL号 : MFCD00006914
存储条件：

粉末 Keep in dark place,Inert atmosphere,Room temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 2 mg/mL(6.62 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • Topo I
描述 Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive CK2 (Casein kinase 2) inhibitor, with an IC50 of 40 nM and a Ki of 20 nM[3]. Ellagic acid (EA; 10 mg/kg/day; p.o., 14 days) strongly decreases MDA brain content by 17%, and reduces the levels of brain TNF-α by 42% in rats. Ellagic acid markedly increases the reduced brain contents of 5-HT (39%), dopamine (DA, 71%), and norepinephrine (NE, 77%). Ellagic acid (10 mg/kg, p.o., 14 days) causes decreased histopathological changes induced by Doxorubicin in rats[4]. Ellagic acid (10 μM) exhibits cytotoxic effects on MCF-7 cells after treatment of radiation. Ellagic acid (10 μM) in combination with Irradiation (IR) significantly abridges the capacity of MCF-7 cells to form colonies equated with individual treatments. Ellagic acid with IR also induces cell apoptosis, and facilitates the upregulation of pro-apopttotic Bax and downregulation of Bcl-2 in MCF-7 cells[5]. The antitumor activity of EA has been mostly attributed to direct antiproliferative and apoptotic effects. Moreover, EA can inhibit tumour cell migration, extra-cellular matrix invasion and angiogenesis[6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00788866 Intrauterine Growth Restrictio... 展开 >>n 收起 << Not Applicable Completed - United States, Missouri ... 展开 >> St Louis Children's Hospital St Louis, Missouri, United States, 63110 收起 <<
NCT02333461 Overweight Ob... 展开 >>esity 收起 << Not Applicable Completed - -
NCT03140280 Myelodysplastic Syndromes Phase 2 Recruiting April 1, 2020 United States, Wisconsin ... 展开 >> Froedtert & the Medical College of Wisconsin Recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Ehab Atallah, MD    414-805-4600    eatallah@mcw.edu    Contact: Medical College of Wisconsin Cancer Center Clinical Trials Office    414-805-8900    cccto@mcw.edu 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.31mL

0.66mL

0.33mL

16.55mL

3.31mL

1.65mL

33.09mL

6.62mL

3.31mL
参考文献

[1]Narayanan BA, Geoffroy O, et al. p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett. 1999 Mar 1;136(2):215-21.

[2]Mandal S, Shivapurkar NM, et al. Inhibition of N-nitrosobenzylmethylamine metabolism and DNA binding in cultured rat esophagus by ellagic acid. Carcinogenesis. 1988 Jul;9(7):1313-6.

[3]Cozza G, Bonvini P, Zorzi E, Poletto G, Pagano MA, Sarno S, Donella-Deana A, Zagotto G, Rosolen A, Pinna LA, Meggio F, Moro S. Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem. 2006 Apr 20;49(8):2363-6

[4]Rizk HA, Masoud MA, Maher OW. Prophylactic effects of ellagic acid and rosmarinic acid on doxorubicin-induced neurotoxicity in rats. J Biochem Mol Toxicol. 2017 Dec;31(12)

[5]Ahire V, Kumar A, Mishra KP, Kulkarni G. Ellagic Acid Enhances Apoptotic Sensitivity of Breast Cancer Cells to γ-Radiation. Nutr Cancer. 2017 Aug-Sep;69(6):904-910

[6]Ceci C, Lacal PM, Tentori L, De Martino MG, Miano R, Graziani G. Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. Nutrients. 2018 Nov 14;10(11):1756